Shanghai United Imaging Healthcare (688271) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 2.48 billion, up 5.42% year-over-year.

• Net profit attributable to shareholders was RMB 370.08 million, a 1.87% increase year-over-year.

• R&D investment rose 12.01% to RMB 567.85 million, representing 22.92% of revenue.

Financial highlights

• Operating profit for Q1 2025 was RMB 398.76 million, nearly flat compared to RMB 400.41 million last year.

• Basic and diluted EPS both at RMB 0.45, up from RMB 0.44 year-over-year.

• Net cash flow from operating activities improved to -RMB 353.47 million from -RMB 657.05 million year-over-year.

• Total assets at quarter-end were RMB 28.85 billion, up 2.89% from year-end 2024.

• Shareholders’ equity increased 1.91% to RMB 20.28 billion.

Key financial ratios and metrics

• Gross margin remained stable with cost of sales at RMB 1.24 billion.

• Weighted average ROE was 1.84%, down 0.07 percentage points year-over-year.

• R&D expense ratio increased by 1.35 percentage points to 22.92%.